Dr. Martin on the Rationale to Evaluate Real-World Outcomes in MCL

Partner | Cancer Centers | <b>Weill Cornell Sandra & Edward Meyer Cancer Center</b>

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

Peter Martin, MD, chief of the Lymphoma Program at the Meyer Cancer Center and an associate professor of medicine at Weill Cornell Medicine, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma (MCL).

During the 2021 ASCO Annual Meeting, investigators presented findings from a retrospective analysis evaluating the clinical outcomes of treatment patterns employed in adult patients with MCL from largely community-based practices in the United States.

Over the past decade, clinical outcomes for patients with MCL have been dramatically improved in the context of clinical trials, Martin says. Typically, younger patients receive intensive, consolidative induction therapy with maintenance, whereas older patients receive bendamustine plus rituximab (Rituxan)–based therapy. However, little is known about real-world treatment patterns and clinical outcomes for patients with MCL treated outside of an academic institution, Martin explains.

As such, the analysis sought to shed light on standard treatment patterns utilized in the community setting, understand clinical outcomes of this patient population, and identify the role of stem cell transplant in younger patients with MCL, concludes Martin.